Genzyme Lemtrada’s Momentum Halts With FDA “Refuse-To File” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
The company says a data formatting issue was the reason FDA declined to accept the supplemental application for alemtuzumab for relapsing multiple sclerosis.